Rilpivirine:anovelnon-nucleoside reversetranscriptaseinhibitor

[1]  M. Stevens,et al.  The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) , 2008 .

[2]  K. King,et al.  Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir , 2008, Journal of clinical pharmacology.

[3]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[4]  A. Kashuba,et al.  Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  I. Frank,et al.  Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers * , 2007, HIV medicine.

[6]  Frank Goebel,et al.  Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects , 2006, AIDS.

[7]  Virginia Cafaro,et al.  Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. , 2006, Journal of acquired immune deficiency syndromes.

[8]  B. Gazzard,et al.  Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers , 2006, AIDS.

[9]  Patrick F. Smith,et al.  Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers , 2006, Pharmacotherapy.

[10]  A. Winston,et al.  Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. , 2005, Journal of Antimicrobial Chemotherapy.

[11]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[12]  G. di Perri,et al.  Pharmacokinetics of saquinavir co-administered with cimetidine. , 2002, The Journal of antimicrobial chemotherapy.